Report cover image

Conjunctivitis Treatment Market Size - By Drug Class (Antibiotic, Antiviral, Anti-Allergic), Disease Class (Bacterial, Viral, Allergic), Route of Administration (Topical, Oral), Formulation Type, Distribution Channel & Forecast, 2024 - 2032

Publisher Global Market Insights
Published Mar 01, 2024
Length 210 Pages
SKU # GMI18789788

Description

Conjunctivitis Treatment Market Size - By Drug Class (Antibiotic, Antiviral, Anti-Allergic), Disease Class (Bacterial, Viral, Allergic), Route of Administration (Topical, Oral), Formulation Type, Distribution Channel & Forecast, 2024 - 2032


Global conjunctivitis treatment market size is expected to observe 4.8% CAGR from 2024 to 2032, driven by the rising prevalence of eye infections worldwide and the increasing demand for effective treatment options. According to American Academy of Ophthalmology (AAO), nearly 1.5 million Americans have late age-related macular degeneration (AMD). The growing elderly population, heightened awareness about eye health, and advancements in healthcare infrastructure are bolstering the market expansion. These drivers, coupled with the ongoing R&D efforts to introduce innovative therapies are indicating a promising outlook for the market growth in the foreseeable future.

The conjunctivitis treatment market is segmented into drug class, disease class, route of administration, formulation type, distribution channel, end-use and region.

The industry share from the antiviral drug class segment is anticipated to record 5.4% CAGR from 2024 to 2032 attributed to the rising incidence of viral conjunctivitis cases globally. Antiviral drugs have shown promising results in treating viral conjunctivitis by targeting the underlying viral infection. With ongoing R&D activities aimed at introducing more potent and efficient antiviral medications, the segment is expected to expand in the coming years.

By distribution channel, the online pharmacies distribution channel segment will garner 5.4% CAGR in the conjunctivitis treatment industry through 2032. This is primarily due to the increasing penetration of internet services and the growing preference for online purchasing among consumers. Online pharmacies offer convenience, accessibility, and a wide range of products to consumers, driving their popularity as a preferred distribution channel for various healthcare products, including conjunctivitis treatment medications. Additionally, the COVID-19 pandemic accelerated the adoption of online pharmacies as consumers prioritize safety and social distancing measures.

Europe conjunctivitis treatment market size will expand at 4.3% CAGR till 2032 due to the presence of well-established healthcare infrastructure, increasing healthcare expenditure, and a high prevalence of eye infections in the region. Moreover, supportive government initiatives aimed at promoting eye health awareness and the availability of advanced treatment options will contribute to the regional market growth.

Table of Contents

210 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of conjunctivitis
3.2.1.2 Technological advancements
3.2.1.3 Easy availability and increased awareness levels
3.2.2 Industry pitfalls & challenges
3.2.2.1 Associated adverse effect of drugs and patent expiration
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)
5.1 Key trends
5.2 Antibiotic
5.3 Antiviral
5.4 Anti-allergic
5.5 Artificial tear
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Disease Class, 2018 - 2032 ($ Mn)
6.1 Key trends
6.2 Bacterial conjuctivitis
6.3 Viral conjuctivitis
6.4 Allergic conjuctivitis
6.4.1 Seasonal allergic conjunctivitis
6.4.2 Perennial allergic conjunctivitis
6.4.3 Other allergic conjunctivitis
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)
7.1 Key trends
7.2 Topical
7.3 Oral
Chapter 8 Market Estimates and Forecast, By Formulation Type, 2018 - 2032 ($ Mn)
8.1 Key trends
8.2 Tablets and capsules
8.3 Ointment
8.4 Drops
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Online pharmacies
9.4 Retail pharmacies & drug stores
9.5 Other distribution channels
Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 AFT Pharmaceuticals
11.3 Ajanta Pharma Limited
11.4 Alembic Pharmaceuticals
11.5 Bausch & Lomb Incorporated
11.6 Cipla, Inc.
11.7 JAWA Pharmaceuticals Pvt. Ltd.
11.8 Novartis AG
11.9 NicOx SA
11.10 Ocular Therapeutics, Inc.
11.11 Santen Pharmaceuticals Co. Ltd.
11.12 Sun Pharmaceuticals Industries Ltd.
11.13 Spectra Vision Care Pvt. Ltd.
11.14 Teva Pharmaceutical Industries Ltd.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us